FDCC
QNCX icon

Foster Dykema Cabot & Co’s Quince Therapeutics QNCX Stock Holding History

Foster Dykema Cabot & Co’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15
Closed -$281K – 97
2021
Q3 		$281K Buy
+15
New +$239K 0.04% 80

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Foster Dykema Cabot & Co's QNCX Position: Q4 2021 in Review

Foster Dykema Cabot & Co sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 15 shares — an estimated $281K sold.

Foster Dykema Cabot & Co first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $281K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Foster Dykema Cabot & Co reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 15 Quince Therapeutics shares in Q4 2021, an estimated $281K.
  • Foster Dykema Cabot & Co first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Quince Therapeutics position peaked at $281K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Foster Dykema Cabot & Co's 13F filing for Q4 2021, filed 9 Feb 2022.